Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza
NCT05227001 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this clinical trial is to learn about the safety and effects of the study vaccine for the potential prevention of influenza. The study vaccine is called Self-Amplifying Ribonucleic Acid vaccine (saRNA vaccine). This study is seeking participants who: * Are between the age of 18 to 49 years old. * Are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. * Are healthy as determined by medical history, physical examinations, and the study doctor. * For male participants, can father children and willing to use an acceptable method of contraception. Female participants who are not of childbearing potential; or male participant not able to father children. * Are capable of giving signed informed consent. Participants will receive either the saRNA vaccine, a licensed Influenza Vaccine (QIV) or a placebo. Participants will not know which vaccine they receive in advance. A placebo does not have any medicine in it but looks just like the study medicine. Participants will receive the study vaccines as a single shot in the arm. We will compare participant experiences to help us determine if the saRNA vaccine is safe and effective. Participants will take part in this study for 6 months. During this time, they will receive the study vaccine and participate in follow-up visits.
Conditions Studied
Interventions
- BIOLOGICAL PF-07852352 Influenza saRNA 1
- BIOLOGICAL PF-07836391 Influenza saRNA
- BIOLOGICAL PF-07836394 Influenza saRNA
- BIOLOGICAL PF-07836395 Influenza saRNA
- BIOLOGICAL PF-07836396 Influenza saRNA
Study Locations (20)
Florida
- Finlay Medical Research — Greenacres City
- Advanced Pharma CR, LLC — Miami
- Miami Clinical Research — Miami
- Mount Sinai Hospital — Miami Beach
- Panax Clinical Research — Miami Lakes
- Pines Care Research Center, LLC — Pembroke Pines
- Pinnacle Health Care Center — Pembroke Pines
- Comprehensive Cardiology Consultants — Pembroke Pines
New York
- NYU Langone Health — New York
- SUNY Upstate Medical University Global Health Laboratory — Syracuse
- SUNY Upstate Medical University Institute for Global Health — Syracuse
- SUNY Upstate Medical University — Syracuse
Arizona
- Arizona Heart Rhythm Center — Phoenix
- Hope Research Institute — Phoenix
- The Pain Center of Arizona — Phoenix
Nebraska
- Pioneer Heart Institute — Lincoln
- Velocity Clinical Research, Omaha — Omaha
California
- Diablo Clinical Research, Inc. — Walnut Creek
Illinois
- Great Lakes Clinical Trials - Andersonville — Chicago
Ohio
- CTI Clinical Research Center — Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2022-04-28 |
| Est. Completion | 2023-08-04 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05227001
The ClinicalTrials.gov registry entry for NCT05227001 describes a study currently listed as completed. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 440 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Influenza, Human appearing as the primary indexed condition, and to 5 interventions — of which PF-07852352 Influenza saRNA 1 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05227001 reports 20 study locations spanning 7 distinct geographic areas — top geographies include Florida, New York, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05227001 about?
NCT05227001 is a clinical study titled "A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza". The purpose of this clinical trial is to learn about the safety and effects of the study vaccine for the potential prevention of influenza. The study vaccine is called Self-Amplifying Ribonucleic Acid vaccine (saRNA vaccine). This study is seeking participants who: * Are between the age of 18 to 49...
What is the current status of trial NCT05227001?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 440 participants. The study started on 2022-04-28. Estimated completion is 2023-08-04.
What conditions does trial NCT05227001 study?
This clinical trial studies the following conditions: Influenza, Human. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05227001?
The interventions under investigation include: PF-07852352 Influenza saRNA 1 (BIOLOGICAL), PF-07836391 Influenza saRNA (BIOLOGICAL), PF-07836394 Influenza saRNA (BIOLOGICAL), PF-07836395 Influenza saRNA (BIOLOGICAL), PF-07836396 Influenza saRNA (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05227001?
This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05227001 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.